Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11039MR)

This product GTTS-WQ11039MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB2&ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3; NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 2065
UniProt ID P04626; P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11039MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7812MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ6708MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ6443MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ8640MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ13398MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ10243MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ13865MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ3213MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARGX-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW